Brief: Schott Pharma - Confirms Recently Increased 2026 Financial Year Guidance
12/08/2026 06:15
BRIEF-Schott Pharma - Confirms Recently Increased 2026 Financial Year Guidance Aug 12 (Reuters) - SCHOTT PHARMA AG & Co. KGaA 1SXP.DE:
SCHOTT PHARMA WITH STRONG Q3 AND ON TRACK FOR PLANNED GROWTH
CONFIRMS RECENTLY INCREASED 2026 FINANCIAL YEAR GUIDANCE
REVENUE GROWTH IN Q3 OF 8.3% AT CONSTANT CURRENCIES (REPORTED: 10.0%)
EBITDA MARGIN OF 26.8% IN Q3
Source text: ID:nEQ26VgWNa
Further company coverage: 1SXP.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on SCHOTT Pharma AG & Co. KGaA
See all newsEurope Research Roundup: GSK, Schott Pharma, Vodafone
SCHOTT Pharma rises after J.P. Morgan initiates with 'Overweight'
Schott Pharma rises after Barclays upgrades to 'overweight' on accelerating growth outlook
Europe Research Roundup: Adyen, GYM Group, Rolls Royce
Brief: Schott Pharma - Confirms Recently Increased 2026 Financial Year Guidance